Continuous supplementation of Avemar along with the anticancer therapies proved to be beneficial for colorectal cancer patients in terms of overall and progression-free survival. Furthermore the inhibition of RR and COX enzymes resulted in significant antitumor effects in patients suffering from colon carcinoma.
Avemar has also shown significant metastasis inhibiting effect in several tumour models without eliciting toxic side effects. Meanwhile the anti-proliferative, apoptotic, adhesion-related and the free radical-forming effects of Avemar may also contribute to the less number of metastases observed in the experimental group. Based on the results Avemar has a supportive value and highly recommended in the treatment of colorectal cancer.
View the publications »